News

Each year BASL presents the Dame Sheila Sherlock research prize, one of the highlights of the annual meeting. This prize is awarded annually to recognise the enormous contribution of Dame Sheila Sherlock to the development of Hepatology as a discipline in its own right.

Dame Sheila was involved in the foundation of the British Liver Club in 1961, which subsequently evolved into The British Association for the Study of the Liver (BASL). She was one of our past presidents and the first recipient of the BASL Distinguished Service Award.

Eligibility
In keeping with Dame Sheila’s enthusiasm for fostering young researchers, this eponymous research prize is awarded to young investigators without substantive posts in either medicine, science or allied health roles for their research contributions in the field of hepatology.

The winner will receive free registration to the meeting, an award and a prize of £1,000 and an invite to deliver the prize lecture and present their research at the BASL Annual Meeting.

To apply, please send one A4 sheet outlining your research and another A4 sheet listing up to 5 related publications.

NB: one person cannot win the Dame Sheila Sherlock Research Prize and Andy Burroughs Young Investigator Award in the same year. Nor can they win a second award with the same body of work as the first.

You must be a BASL member to apply.

Please send submissions to [email protected] by the deadline of Friday 10th July

BASL is committed to promoting equality, diversity and inclusion in all aspects of its work. It is actively promoting equal opportunities and access for all our members regardless of their background.

The UK Panel for Healthcare Workers Living with Bloodborne Viruses is seeking an expert in hepatology to join its panel.

The United Kingdom Advisory Panel
UKAP gives advice and guidance on the transmission and management of bloodborne viruses (BBVs) among healthcare workers - specifically HIV, hepatitis B and hepatitis C. The panel also provides support for local incident management teams.

Role description
As an expert panel member, you will provide independent advice in your area of expertise to UKAP. We are looking for an outstanding individual, with proven expertise in hepatitis treatment, epidemiology and/or hepatitis B, C and D virology. You will have a commitment to:
• Providing evidence-based advice
• Maintaining the independent integrity of UKAP
• The values of accountability and probity
• Following the best practice principles as set out in the Code of Practice for Scientific Advisory Committees and Councils1

All applicants should have:
1. Strong skills in absorbing and analysing information and scientific or medical data, including:
• Applying relevant knowledge, perspective, and skills
• Identifying key issues and actions needed
• Developing evidence-based, workable solutions to sometimes complex issues
2. Excellent communication skills, including:
• Engaging effectively with, and using knowledge and skills to make, impartial and persuasive arguments based on a sound understanding of the evidence available
• Providing effective challenge in face-to-face discussions and telephone conferences
3. Experience at a senior level, including:
• Making significant personal contributions to a particular field of study
• Commitment to the principles of giving independent advice to stakeholders and/or government
• Sound understanding of and commitment to the principles of public life and equalities

The time commitment is 6-8 days per year.
The Chief Executive of UKHSA determines the length of appointment, which may be for up to a maximum of 3 years.
There is no remuneration for this post, but expenses will be paid in line with UKHSA policy.

To apply please email your CV and supporting statement to [email protected] 

The closing date for applications is the 16th July 2026

Code of Practice for Scientific Advisory Committees and Councils: CoPSAC 2021
https://www.gov.uk/government/publications/scientific-advisory-committees-code-of-practice/code-of-practice-for-scientific-advisory-committees-and-councils-copsac-2021 

On behalf of Gilead Sciences Ltd.  

The Gilead UK & Ireland Viral Hepatitis and BBV Testing Fellowship and Medical Grants Programme funds innovative projects and initiatives that can ultimately lead to an improvement in awareness and diagnosis of viral hepatitis (B, C and Delta) and/or demonstrate the proof of concept/pilot Opt-Out testing of BBV (HBV, HCV, HDV and HIV). 

Applications are invited from healthcare and third sector organisations (e.g., charities) who are seeking funding for a project that aligns with the goals of the programme. Please be advised that only health-related organisations are eligible to receive grants through this application process. Individual applicants are not eligible for funding. 

The programme is looking to support innovative projects and initiatives that: 

• Improve awareness and diagnosis of viral hepatitis (B, C, and Delta), including among migrant and other underserved communities 
• Demonstrate proof of concept and/or pilot opt-out BBV testing across a broader range of healthcare and community settings where high prevalence rates of HBV, HCV, HDV and HIV are expected (e.g., primary care, women’s health hubs, psychiatry services, migrant health services, and services targeting underserved populations) 
• Optimise linkage to care and/or management for people living with viral hepatitis (B, C, and Delta), including peer support 
• Evaluate innovative approaches to optimising patient pathways and enabling rapid access to care for those newly diagnosed with viral hepatitis (B, C, and Delta) 
• Enhance patient support programmes and tools for people living with viral hepatitis (B, C, and Delta), with a focus on addressing stigma, community outreach and engagement, disease awareness, and prevention of transmission 
• Improve understanding of, and reduce, variations in care for people living with viral hepatitis (B, C, and Delta), and improve the experiences of people from marginalised communities 
• Improve the use of data to diagnose people with viral hepatitis (B, C, and Delta) and to identify those lost to follow-up 
• Assess the societal and health economic implications of hepatitis B and Delta 

The application window will close on Friday 22nd May 2026. More information about the Gilead UK & Ireland Viral Hepatitis and BBV Testing Fellowship and Medical Grants Programme, is available on the Gilead UK and Ireland website > HERE. 

Any questions regarding the process or the application form can be directed to [email protected] .

Date of prepartion: April 2026
Code: UKI-UNB-2707

BASL is seeking nominations for a number of Special Interest Group (SIG) Leads as the current leads have come to the end of their tenure. These SIGs are linked to the NIHR’s Research Delivery Network (RDN) topic areas.

SIG Leads will serve for two years and the posts currently up for change are as listed below:

• Acute Liver Failure (ALF) SIG
• Alcohol related Liver Disease (ArLD) SIG
• Cholangiocarcinoma-UK (CCA-UK) SIG
• Immune-Mediated Liver Disease SIG
• Metabolic Dysfunction–Associated Liver Disease (MASLD) SIG
• Palliative Hepatology SIG
• Portal Hypertension SIG
• Rare Diseases SIG

NB: SIG Leads are required to be a BASL member.

Further information for each of the SIGs may be found on the BASL website HERE

The role of the SIG Lead can be found in the BASL/BSG Special Interest Groups (SIGs) Terms of Reference  Download SIGs_generic_terms_of_reference_2026.pdf

Eligibility requirements

• Candidates wishing to be considered for nomination must be a BASL member or a member of the relevant SIG their nomination is for.
• Each candidate must have a proposer and seconder, who should also be a BASL member or an associate member through the relevant SIG.

Nomination process

• Please send nominations by email clearly stating the SIG Lead position that your nomination is for to the BASL Secretariat at [email protected] by 17:00 on 12th May 2026.
• Candidates wishing to be considered for nomination must be a member of BASL and will require one BASL / SIG member to propose them and a second BASL / SIG member to second their nomination.
• If only one candidate is proposed and seconded, that candidate will be elected unopposed as the appropriate SIG Lead.
• If two or more candidates are nominated, eligible candidates will be asked to submit a personal statement of up to 300 words. The Secretariat will then arrange for an election where members of the appropriate SIG will be invited to vote.
• The successful candidate/s will be elected by a simple majority of those members voting to the appropriate SIG Lead post.

BASL is committed to promoting equality, diversity and inclusion in all aspects of its work. It is actively promoting equal opportunities and access for all our members regardless of their background.  We would, therefore, encourage you to consider this role to help shape the future of BASL and increase our inclusivity/inclusiveness.

Please contact [email protected] if you require any further information.

Funding is for 2 Clinical Research Fellows in Hepatology to contribute to the further development of an extensive research program. These posts will commence in September on a fixed term contract for 12 months in the first instance, renewable for a maximum of 3 years depending on progress towards an MD or PhD.

There has been significant investment and growth in liver research at the Peninsula Medical School, with excellent laboratory facilities present adjacent to Derriford Hospital at the Derriford Research Facility where the Hepatology Research Group ( https://www.plymouth.ac.uk/research/hepatology-research-group ) and the Centre of Environmental Hepatology (https://www.plymouth.ac.uk/research/centre-of-environmental-hepatology ) are based. Active clinical research programs span alcohol related liver disease, the use of big data and AI for early liver disease detection, to mechanisms of protection from viral hepatitis. The Centre of Environmental Hepatology, led by Professor Shilpa Chokshi, has a cutting edge and expanding program of translational and basic science work looking at the impact of micro- and nanolastics on liver health. The research programs are delivered and supported by a strong team of senior post-doctoral scientists, clinical research fellows, and PhD students.

Read and apply via the NHS Jobs website under reference 216-G3-HEP7796852

Closing date extended to 20th April 2026

Informal enquiries welcomed with interviews scheduled for April - please contact Professor Matthew Cramp or Professor Ashwin Dhanda, [email protected] or [email protected].